Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 6
2005 11
2006 13
2007 30
2008 29
2009 41
2010 58
2011 84
2012 91
2013 102
2014 83
2015 83
2016 77
2017 54
2018 48
2019 45
2020 44
2021 32
2022 26
2023 25
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

854 results

Results by year

Filters applied: . Clear all
Page 1
Zotarolimus (ABT-578) eluting stents.
Burke SE, Kuntz RE, Schwartz LB. Burke SE, et al. Adv Drug Deliv Rev. 2006 Jun 3;58(3):437-46. doi: 10.1016/j.addr.2006.01.021. Epub 2006 Mar 6. Adv Drug Deliv Rev. 2006. PMID: 16581153 Review.
This article focuses on the development of stents which elute the potent anti-proliferative agent, zotarolimus, from a synthetic phosphorylcholine-based polymer known for its biocompatible profile. Zotarolimus is the first drug developed specifically for local deliv …
This article focuses on the development of stents which elute the potent anti-proliferative agent, zotarolimus, from a synthetic phos …
Structural Identification of Zotarolimus (ABT-578) Metabolites Generated by Human Liver Microsomes Using Ion-Trap and High-Resolution Time-of-Flight Mass Spectrometry in Combination with the Analysis of Fragmentation Patterns.
Shokati T, Drake SH, Zhao W, Klawitter J, Klawitter J, Christians U. Shokati T, et al. Metabolites. 2023 Oct 19;13(10):1093. doi: 10.3390/metabo13101093. Metabolites. 2023. PMID: 37887418 Free PMC article.
Zotarolimus (ABT-578) is a sirolimus derivative that, like sirolimus and everolimus, is an inhibitor of cell growth via inhibition of the mechanistic target of rapamycin (mTOR). ...Human liver microsomes mainly hydroxylated and/or demethylated zotarolimus …
Zotarolimus (ABT-578) is a sirolimus derivative that, like sirolimus and everolimus, is an inhibitor of cell growth via …
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
Valgimigli M, Wlodarczak A, Tölg R, Merkely B, Kelbæk H, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Honton B, Dietrich PL, Stammen F, Ferdinande B, Silvain J, Capodanno D, Cayla G; Bioflow-DAPT Investigators. Valgimigli M, et al. Circulation. 2023 Sep 26;148(13):989-999. doi: 10.1161/CIRCULATIONAHA.123.065448. Epub 2023 Aug 25. Circulation. 2023. PMID: 37624364 Free PMC article. Clinical Trial.
The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of dual antiplatelet therapy after PCI. ...Patients …
The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-poly …
Panta rhei, also drug eluting stent technology.
Chiarito M, Mehran R. Chiarito M, et al. Catheter Cardiovasc Interv. 2020 May 1;95(6):1074-1075. doi: 10.1002/ccd.28918. Catheter Cardiovasc Interv. 2020. PMID: 32421244
The Resolute zotarolimus eluting stent (ZES) is a next-generation durable polymer, thin-struts drug eluting stent. ...
The Resolute zotarolimus eluting stent (ZES) is a next-generation durable polymer, thin-struts drug eluting stent. ...
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJ; ENDEAVOR IV Investigators. Leon MB, et al. JACC Cardiovasc Interv. 2009 Dec;2(12):1208-18. doi: 10.1016/j.jcin.2009.10.008. JACC Cardiovasc Interv. 2009. PMID: 20129547 Free article. Clinical Trial.
OBJECTIVES: The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES) in patients with native coronary lesions. ...METHODS: The ENDEAVOR …
OBJECTIVES: The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimu …
A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.
Karyekar CS, Pradhan RS, Freeney T, Ji Q, Edeki T, Chiu W, Awni WM, Locke C, Schwartz LB, Granneman RG, O'Dea R. Karyekar CS, et al. J Clin Pharmacol. 2005 Aug;45(8):910-8. doi: 10.1177/0091270005278807. J Clin Pharmacol. 2005. PMID: 16027401 Clinical Trial.
ABT-578 pharmacokinetics was described by a 3-compartment open model. ...ABT-578 was shown to be safe over a wide range of systemic exposures....
ABT-578 pharmacokinetics was described by a 3-compartment open model. ...ABT-578 was shown to be safe over a wid …
Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
Rozemeijer R, Benedetto D, Kraaijeveld AO, Voskuil M, Stein M, Timmers L, Rittersma SZ, Agostoni P, Doevendans PA, Stella PR. Rozemeijer R, et al. Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):521-525. doi: 10.1016/j.carrev.2017.10.011. Epub 2017 Oct 26. Cardiovasc Revasc Med. 2018. PMID: 29137966
OBJECTIVE: To assess clinical outcomes of Amphilimus Sirolimus-Eluting Stents (A-SES) as compared to Zotarolimus-Eluting Stents (ZES) in complex real-world diabetic patients. ...
OBJECTIVE: To assess clinical outcomes of Amphilimus Sirolimus-Eluting Stents (A-SES) as compared to Zotarolimus-Eluting Stents (ZES) …
One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R, van Muiden IG, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Doevendans PA, Voskuil M, Stella PR. Rozemeijer R, et al. Catheter Cardiovasc Interv. 2019 Jul 1;94(1):61-69. doi: 10.1002/ccd.28041. Epub 2019 Jan 2. Catheter Cardiovasc Interv. 2019. PMID: 30604493 Free PMC article.
We aimed to assess 1-year clinical outcomes of PF-AES as compared to latest-generation permanent polymer zotarolimus-eluting stents (PP-ZES) in a real-world all-comers setting. ...
We aimed to assess 1-year clinical outcomes of PF-AES as compared to latest-generation permanent polymer zotarolimus-eluting stents ( …
Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model.
Collingwood R, Gibson L, Sedlik S, Virmani R, Carter AJ. Collingwood R, et al. Catheter Cardiovasc Interv. 2005 Jun;65(2):227-32. doi: 10.1002/ccd.20348. Catheter Cardiovasc Interv. 2005. PMID: 15900559
The objective of this study was to determine the feasibility and efficacy of stent-based delivery of ABT-578, a structurally unique macrocyclic lactone. Stainless steel balloon-expandable stents were coated with thin layer of phosphorylcholine (PC) or PC with ABT …
The objective of this study was to determine the feasibility and efficacy of stent-based delivery of ABT-578, a structurally u …
The Day After a Primary Endpoint.
Kandzari DE. Kandzari DE. JACC Cardiovasc Interv. 2018 Mar 12;11(5):470-472. doi: 10.1016/j.jcin.2017.12.008. JACC Cardiovasc Interv. 2018. PMID: 29519379 Free article. No abstract available.
854 results